Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Trials & Tribulations

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

Clinical Roundup

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Montefiore Einstein sees lowest rate of late-stage lung cancer diagnoses in surrounding community

For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.

November 21, 2025

Vol.51 No.43

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

YOU MAY BE INTERESTED IN

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Montefiore Einstein sees lowest rate of late-stage lung cancer diagnoses in surrounding community

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login